4579 — RaQualia Pharma Income Statement
0.000.00%
Last trade - 00:00Annual income statement for RaQualia Pharma, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
| Standards: | — | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2,776 | 2,918 | 1,901 | 3,108 | 3,980 |
| Cost of Revenue | |||||
| Gross Profit | 2,456 | 2,686 | 1,656 | 2,482 | 3,268 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 2,088 | 2,117 | 2,260 | 3,344 | 3,470 |
| Operating Profit | 688 | 801 | -359 | -237 | 510 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 881 | 851 | -294 | -358 | 438 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 756 | 723 | -324 | -495 | 273 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 756 | 723 | -324 | -495 | 273 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 756 | 723 | -324 | -495 | 273 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 36.8 | 37.1 | -14.3 | -12.8 | 22.5 |
| Dividends per Share |